Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
复制标题
非小细胞肺癌化疗前后肿瘤细胞上程序性死亡配体 1 的表达存在差异。
DOI：
10.1038/srep20090
复制
发表时间：
2016-01-29
影响因子：
4.6
通讯作者：
Zhang L
中科院分区：
文献类型：
--
作者：
Sheng J;Fang W;Yu J;Chen N;Zhan J;Ma Y;Yang Y;Huang Y;Zhao H;Zhang L
治疗对程序性死亡配体 1 (PD-L1) 表达的影响尚不清楚。本研究的目的是探讨新辅助化疗（NACT）对非小细胞肺癌（NSCLC）患者PD-L1表达的影响。采用免疫组织化学 (IHC) 方法检测 NACT 前后 32 例配对肿瘤标本中的 PD-L1 表达。 NACT 后肿瘤细胞 (TC) 上的 PD-L1 阳性率从 75% 变为 37.5% (p = 0.003)。 IHC评分为1、2、3的病例均出现明显下降（p = 0.007）。然而，肿瘤浸润免疫细胞（IC）没有观察到显着变化（p = 0.337）。亚组分析和半定量分析均得出相似的结果。此外，对 NACT 有反应的患者在 TC 上的 PD-L1 表达显着降低 (p = 0.004)。尽管未得到 Cox 比例风险回归模型的证实，但 PD-L1 状态从阴性转为阳性的组与相反组之间的无病生存率 (DFS) 存在明显差异（中位 DFS：9.6 与 25.9，p = 0.005）。我们的数据显示，NSCLC 的既往化疗可能会导致 PD-L1 表达不一致。建议在治疗期间和连续样本上（至少在最新的肿瘤样本上）监测 PD-L1 表达。
The effects of treatments to programmed death ligand-1 (PD-L1) expression is unknown. The aim of this study was to investigate the impact of neoadjuvant chemotherapy (NACT) on PD-L1 expression in non-small cell lung cancer (NSCLC) patients. PD-L1 expression was detected by immunohistochemistry (IHC) method in 32 paired tumor specimens pre and post-NACT. The positivity of PD-L1 on tumor cells (TCs) changed from 75% to 37.5% after NACT (p = 0.003). Cases with IHC score of 1, 2, 3 all underwent apparent decrease (p = 0.007). However, no significant changes were observed on tumour-infiltrating immune cells (ICs) (p = 0.337). Subgroup and semiquantitative analyses all presented similar results. Moreover, patients with response to NACT presented significantly reduced PD-L1 expression on TCs (p = 0.004). Although it was not confirmed by the Cox proportional hazard regression model, there was an apparent difference in disease-free-survival (DFS) between negative-to-positive switch of PD-L1 status and the contrary group (median DFS: 9.6 versus 25.9, p = 0.005). Our data revealed that antecedent chemotherapy for NSCLC may results in inconsistency of PD-L1 expression. PD-L1 expression is suggested to be monitored around treatment and on serial samples, at least, on the latest tumor specimen.